Obesity-Related Increased ?? Fibrinogen Concentration in Children and Its Reduction by a Physical Activity-Based Lifestyle Intervention: A Randomized Controlled Study - 23/07/13
Abstract |
Objective |
To determine if elevated plasma γ′-fibrinogen, typically involved in the formation of fibrinolysis-resistant clots, confers an increased risk for cardiovascular disease (CVD) and thrombosis in children as it does in adults. Although obesity-related hyperfibrinogenemia is frequently reported in children, the role of γ′ fibrinogen and its response to physical activity-based lifestyle are less clear in this population.
Study design |
In a randomized controlled 3-month physical activity–based lifestyle intervention, γ′ fibrinogen concentration was measured in 21 children (aged 14-18 years; Tanner stage > IV), including 15 in the obese group and 6 in the normal weight group, with body mass index percentiles for age and sex of >95 and <85, respectively.
Results |
The relationships between γ′ fibrinogen and other risk factors for CVD, such as markers of insulin resistance and subclinical inflammation, along with body composition (as measured by dual-energy X-ray absortiometry), were assessed before and after the intervention. γ′ fibrinogen concentration was higher in the obese group compared with the normal weight group (P < .05) and was correlated with other risk factors for CVD (adjusted R2 = 0.9; P < .05), and insulin emerged as the major predictor of γ′ fibrinogen. The intervention reduced γ′-fibrinogen concentration (P < .05).
Conclusion |
Our data reveal: (1) elevated γ′ fibrinogen concentrations in obese insulin-resistant children compared with normal lean controls; (2) a relationship between γ′ fibrinogen and other CVD risk factors; and (3) physical activity–induced reduction in γ′ fibrinogen in obese children.
Le texte complet de cet article est disponible en PDF.Keyword : BMI, BSA, CRP, CVD, DEXA, HOMA-IR, IL, PBS
Plan
P. B. is supported by Nemours Research Programs and the American Heart Association Scientist Development Grant Award. Oregon Health & Science University (OHSU) and D.F. have significant interest in Gamma Therapeutics, a company that may have commercial interest in this research and technology; this potential conflict of interest has been reviewed and managed by OHSU. The other authors declare no conflicts of interest. |
Vol 163 - N° 2
P. 333-338 - août 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?